NEXT GENERATION SEQUENCING IS HERE NOW

Abstract

The availability of massively parallelDNA sequencers has brought the cost ofsequencing genes to affordable levels but thecost of analyzing the huge amount of datahas not decreased to the same extent. Thus,only analyzing the sequences of the genesrelevant to the patient’s condition makes thecost manageable. A panel of genes relevant tolymphedematous conditions is described.